PITTSBURGH–(BUSINESS WIRE)–Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, today announced the passing of long-time and valued member of the company’s Board of Directors, John H. McArthur.
“We are deeply saddened by the passing of John McArthur. He was a dedicated member of Noveome’s Board of Directors for over ten years and provided invaluable insight, support and knowledge. We greatly benefited from his extensive network and credentials in both healthcare and academia, including his 15 years as dean of Harvard Business School,” said William J. Golden, Founder, Chairman and Chief Executive Officer of Noveome. “We appreciate all of his contributions to Noveome and our thoughts are with John’s family.”
About Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues. Noveome’s multi-target platform biologic and lead product, ST266, is currently being evaluated in multiple indications across ophthalmic, CNS, pulmonary, and gastrointestinal therapeutic areas. In addition to the Phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally, Noveome is currently conducting a Phase 2 open-label clinical trial evaluating the efficacy of ST266 in healing PEDs when delivered topically to the eye. Topline data for this trial are expected in 2019. Preclinical results testing ST266 in chronic traumatic encephalopathy (CTE), emphysema, polytrauma, and necrotizing enterocolitis (NEC) are also expected later in 2019. The Company received seed funding from Lancet Capital, a venture capital consortium of leading Pittsburgh healthcare institutions including UPMC Enterprises, Highmark Blue Cross/Blue Shield, University of Pittsburgh and Carnegie Mellon University. To date, Noveome has received over $140 million in research and infrastructure funding from the U.S. Department of Defense, the Commonwealth of Pennsylvania and Allegheny County. Noveome is based in Pittsburgh, PA. For more information, please visit, www.noveome.com.
Contacts
Investor Contact:
Julie Seidel
Stern Investor Relations, Inc.
212-362-1200
julie.seidel@sternir.com